Introduction
Drugs that act on the brain commonly affect multiple areas and brain functions in addition to those that are primarily targeted. While this attribute can be advantageous, and as such is often employed in the treatment of migraine, bipolar disorders and some other CNS impairments, it also may cause certain adverse effects. Levetiracetam (LEV) is a new AED reported to have a high degree of tolerability in both adult and children patients with epilepsy. Moreover, pilot studies have recently been completed to explore the potential utility of LEV in the treatment of affective disorders, and both preclinical data 1 and clinical trials suggest that it may be an effective treatment for bipolar spectrum disorders. 2 At the same time, some studies reported that adverse behavioural and psychiatric events may occur in patients with epilepsy, who receive LEV. In pivotal randomized controlled trials, 13.3% of levetiracetam-treated epilepsy patients reported behavioural symptoms, such as agitation, hostility, anxiety, apathy, emotional lability, as compared with 6.2% of placebo patients. 3, 4 To our best knowledge, we are the first to report a major depressive disorder induced by LEV in a pediatric epilepsy patient.
Case report
A 5-year-old boy was first diagnosed with epilepsy at age of 3 years. He had no familial history. He experienced neonatal cerebral infarction which led to right hemiparesis and partial epilepsy. Several antiepileptic drugs were tried, starting with valproate. An addition of oxcarbazepine caused rash. Therefore, oxcarbazepine was replaced with lamortigine. Finally, because seizures persisted, LEV replaced valproate in addition to lamotrigine. With the latter combination, a striking remission of attacks was observed. Three weeks after the start of LEV therapy, the patient developed lack of appetite (evident as reduced food intake) and insomnia with difficulties initiating sleep. In addition, the parents observed fatigue, irritability, loss of interest for games, and loss of reaction to pleasurable stimuli. He stopped playing with sibling and did not show interest in any activities. Instead, he spent long time lying in bed. Furthermore, according to his mother, he experienced a diminished ability to concentrate. Finally, aggressive behaviours were observed at school. Four weeks after the onset of the symptoms, he was admitted to our department. LEV was discontinued and clobazam was started. Two weeks later, the symptoms of depression completely disappeared, and the patient returned to previous functioning.
Discussion
We are the first to report LEV-induced depression in a child with epilepsy. Previously, the patient never experienced any psychiatric Depression in children and adolescents with epilepsy is common. Depression worsen quality of life in epilepsy patients. Neurobiological, social, and iatrogenic factors may play a role in depressive disorder development. We report a patient with partial epilepsy secondary to neonatal stroke, who developed depressive disorder as a result of levetiracetam (LEV) treatment. Our report illustrates the possible implication of iatrogenic factors in depression among epilepsy patients. However, recent data suggest that LEV may be effective in case of affective disorders. We discuss the factors linking epilepsy with depression. Because of its high incidence and its multiple physiopathologic factors, psychiatric comorbidity should be always assessed in pediatric epileptic patients.
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or behavioural symptoms. He developed major depressive episode according to the DSM (Diagnostic and Statistical Manual) IV-R criteria. The onset of depressive symptoms was observed 3 weeks after the start of LEV although the seizures were under control by the AED. Interestingly, he returned to his previous state 2 weeks after the discontinuation of LEV without time to start psychotherapy. We did not find any life event which could explain the symptoms of depression. Taking into the account all the mentioned details, we concluded that major depressive episode in our patient was a result of LEV treatment. Children with epilepsy are more vulnerable to psychiatric disorders than general population. Furthermore, the incidence of depression among pediatric patients with epilepsy is higher than in other chronic childhood diseases. Several factors may contribute to emotional symptoms in the specific disorder of epilepsy. These influences include CNS variables (e.g., effects of seizures, concomitant CNS conditions giving rise to seizures, and medications), as well as psychosocial factors (e.g., the stigma of having seizures). Experimental studies have shown that depression develops under conditions of animal models of absence epilepsy (particularly in the genetic absence epilepsy rat from Strasbourg 5 ), as well as temporal lobe epilepsy. 6, 7 AED may also be involved in pathophysiology of mood disorders in epileptic patients. GABAergic drugs exhibit negative effect on mood while carbamazepine and lamotrigine appear to influence it positively. 8, 9 The barbiturates, vigabatrin and topiramate show greater associations with the occurrence of depressive symptoms than other antiepileptic drugs, presenting in up to 10% of all patients, but even more so in susceptible patients. Phenytoin, ethosuximide, carbamazepine, oxcarbazepine, gabapentin, valproate, pregabalin and lamotrigine are all associated with low risks for depression (<1%), and several of these antiepileptic drugs seem to have a positive effect on mood. 9 Regarding LEV treatment, there are several reports on behavioural and psychiatric side effects. The most frequent complaints have been irritability, nervousness, hostility and anxiety.
3,4 A medically and psychiatrically healthy woman developed symptoms consistent with major depressive disorder while she was under LEV. 10 At the same time, several studies reported therapeutic effects of LEV on anxiety and/or depression. 2, 11 In conclusion, the reported case illustrates the importance of careful monitoring of behavioural effects of AED. To our knowledge, this is the first reported case of depression induced by levetiracetam in children. Depression in childhood is frequently underdiagnosed. Because of its high incidence and its multiple physiopathologic factors, psychiatric comorbidity should be always assessed in pediatric epileptic patients.
